Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study by Na Cui et al.
RESEARCH ARTICLE Open Access
Initial therapeutic strategy of invasive
candidiasis for intensive care unit patients:
a retrospective analysis from the China-
SCAN study
Na Cui1, Hao Wang1, Longxiang Su1, Haibo Qiu2, Ruoyu Li3, Dawei Liu1* and on behalf of the China-SCAN Team
Abstract
Background: To investigate the impact of initial antifungal therapeutic strategies on the prognosis of invasive
Candida infections (ICIs) in intensive care units (ICUs) in China.
Methods: A total of 306 patients with proven ICIs in the China-SCAN study were analyzed retrospectively. Empiric,
pre-emptive, and targeted therapy were adopted based on starting criteria including clinical, microbiological, and
other conventional prediction rules. The primary outcome was hospital mortality and the secondary endpoints were
duration days in ICU and duration days in hospital. The global responses (clinical and microbiological) at the end of
the empirical therapy were also assessed.
Results: A total of 268/306 (87.6%) ICI patients received antifungal therapy, including 142/268 (53.0%) initial
empirical therapy, 53/268 (19.8%) initial pre-emptive therapy, and 73/268 (27.2%) initial targeted therapy.
Compared with the initial empirical antifungal therapy and targeted antifungal therapy, patients with initial
pre-emptive antifungal therapy had significantly less clinical remission [11/53 (21.2%) vs. 61/142 (43.3%) vs.
22/73 (30.1%), P = 0.009], higher ICU [26/53 (57.8%) vs. 42/142 (32.2%) vs. 27/73 (43.5%), P = 0.008] and hospital
mortality [27/53 (60.0%) vs. 43/142 (32.8%) vs. 29/73 (46.8%), P = 0.004] and more microbiological persistence
[9/53 (17.0%) vs. 6/142 (4.2%) vs. 9/73 (12.3%), P = 0.011]. Kaplan-Meier survival analysis revealed that ICI
patients with initial pre-emptive antifungal therapy and targeted antifungal therapy were associated with
reduced hospital duration compared with patients with initial empirical antifungal therapy after confirmation
of fungal infection (log-rank test: P = 0.021). Multivariate regression analysis provided evidence that initial
empirical antifungal therapy was an independent predictor for DECREASING the hospital mortality in ICI
patients on ICU admission and at ICI diagnosis (odds ratio 0.327, 95% confidence interval 0.160–0.667,
P = 0.002; odds ratio 0.351, 95% confidence interval 0.168–0.735, P = 0.006).
Conclusions: The initial therapeutic strategy for invasive candidiasis was independently associated with
hospital mortality. Prompt empirical antifungal therapy could be critical to decrease early hospital mortality.
Trial registration: Clinicaltrials.gov NCT01253954 (retrospectively registration date: December 3, 2010)
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Background
Invasive fungal infection (IFI) is one of the most com-
mon in opportunistic infections for critically ill patients
[1]. Recently, IFI incidences in intensive care units
(ICUs) have increased year by year with improvements
in hygiene, disease management, and life support tech-
nology [2]. Invasive candidiasis infection (ICI) is the
most common and important part of IFI [3, 4]. Candide-
mia is responsible for 7–10% of nosocomial bloodstream
infections, and Candida is located in the top five most
common pathogens [5–7]. The 6.9 per 1000 candidemia
incidence of ICU patients and 7.5% of prevalence of
antifungal agents administered have been reported [8, 9].
ICI, mostly candidemia, increases the mortality rate,
represents longer lengths of ICU or hospital stay, and
uses a great deal of healthcare expenses and resources
[3, 4, 10]. Thus, finding an appropriate treatment
strategy for the best ICI treatment is an issue that needs
to be resolved.
Anti-infection strategies for ICI are complex processes
that include both clinical diagnosis and treatment; de-
layed treatments worsen the prognosis, drug abuse leads
to antimicrobial drug selection pressure, and wasting
resources is an important clinical problem. Faced with
ICIs in critically ill patients, we urgently need to know
whether giving early empirical antifungal therapy, then
adjusting according to clinical diagnosis circumstances,
or waiting for the microbiological evidence to determine
the start of the antifungal treatment is acceptable or not.
Additionally, knowing the types of evidence to collect
before we begin antifungal therapy would benefit pa-
tients’ prognoses [direct culture detection or surrogate
markers, such as Candida mannan antigens and anti-
mannan antibodies and β-D-glucan, or polymerase-
chainreaction (PCR) assays]. Although many experts and
proposed guidelines suggest prophylaxis, empirical, pre-
emptive, targeted, and other various initial antifungal
treatment strategies, there is no currently available evi-
dence for the effectiveness of previously mentioned
treatments in ICU patients. The China Survey of Can-
didiasis in the ICU (China-SCAN) study was performed
to assess the current incidence, mortality, pathogen
spectrum, management, treatment, and risk factors for
ICI in China’s ICUs [11]. The data from the China-
SCAN study were used to investigate the impact of an
initial antifungal therapeutic strategy on the prognosis of
patients with ICIs in Chinese ICUs. We expect this study
to provide a reasonable basis for how to select antifungal
therapy strategies clinically.
Methods
Study design and patients involved
The China-SCAN study is the largest observational
study on prevalence of ICI in China and was conducted
between November 2009 and April 2011 in 67 partici-
pating ICUs distributed throughout China. The details
of this study, including the study population, inclusion,
and exclusion criteria were previously published [11]. All
the participating hospitals accepted the central ethics
committee (Ethics Committee of Zhongda Hospital of
Southeast University) review or conducted a further, in-
dependent, ethics review according to their own institu-
tional policy. This was registered with ClinicalTrials.gov
(NCT01253954). During the China-SCAN trial, 306 out
of 96,060 ICU patients from 67 centers throughout
China were diagnosed with ICIs by direct detection of
fungal infection. A total of 268/306 (87.6%) patients finally
received antifungal therapy. The remaining 59 patients
withdrew from or decided to forego comprehensive treat-
ment, 29 of whom died in the hospital and 30 of whom
were discharged at their request. Based on the initial anti-
fungal therapeutic strategies received, all the patients in-
cluded were divided into empirical (n = 142), pre-emptive
(n = 53), and targeted (n = 73) therapy groups. Based on
the clinical prognosis of patients who died in the hospital
or completed treatment and were discharged at their
physician’s discretion, the population was further divided
into survivor (n = 139) and non-survivor (n = 99) groups.
Figure 1 presents a flowchart of patient screening and
selection for this study.
Evidence for antifungal treatment and initial antifungal
therapy strategy
Definition of infection
Based on the guidelines for the diagnosis and manage-
ment of candidiasis issued by the Infectious Diseases
Society of America [12] and the European Society of
Clinical Microbiology and Infectious Diseases [13],
the evidence used to treat antifungal infection in the
China-SCAN trial was divided into the following four
categories:
(a) Clinical signs of infection diagnosed by the
opinion of treating physician had to meet two
or more of the following clinical features [14]: (i)
body temperature ≥ 38 or < 36 °C; (ii) respiratory
rate ≥ 30 breaths per min; (iii) pulse rate ≥ 120
beats per min; and (iv) abnormal total peripheral
white blood cell counts ≥ 10,000 or < 4000 per
mm3, or immature neutrophils > 15%.
(b) Risk factors of fungal infection: etiology-related factors
such as neutropenia, hematological diseases, transplant-
ation, surgery, and tumors; treatment-related factors,
such as parenteral nutrition, broad-spectrum antibi-
otics, venous indwelling catheters, and other factors
causing increased rate of fungal infection.
(c) Microbiological evidence: Indirect evidence of
fungal infections: serological parameters including
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Galactomannan and β-D-glucan. The fungal
colonization index was calculated [15]. The Candida
colonization index (CCI) was calculated as the ratio
of the number of culture-positive surveillance sites
to the total number of sites cultured. A CCI ≥ 0.5
was considered as indirect evidence of invasive
candidiasis in this study. Direct detection of fungal
infections: blood and tissue specimens obtained from
normally sterile sites were cultured. One thing to be
mentioned, fungal combined bacterial infection,
or even viral infection occurred in one patient
maybe exist. So co-infection were not be
systematically excluded.
Treatment options and outcomes
By combining evidence for the antifungal treatments
mentioned above and actual clinical situations in main-
land China hospitals, initial antifungal therapy began
when patients met the following clinical features
based on personal choice of the physician: (1) Empir-
ical antifungal therapy: the patients had clinical signs
of infection with any of the risk factors of fungal in-
fection; (2) Pre-emptive antifungal therapy: the pa-
tients must have at least one indirect evidence of a
fungal infection; (3)Targeted antifungal therapy: in
addition to meeting the conditions for empirical anti-
fungal therapy, the patients must have one direct
evidence of a fungal infection.
Complete clinical efficacy was defined as elimination of
all signs and symptoms of ICI, and accompanying radio-
graphic resolution; partial efficacy was defined as improve-
ment rather than complete elimination. Microbiological
elimination was defined as negative culture from the
original infection site.
Statistical analysis
Quantitative data with normal distributions are denoted
as the means ± standard deviations. Student’s t test or
one-way analysis of variance (ANOVA) was performed
to compare the means between the different groups.
Abnormally distributed quantitative data were denoted
using medians (interquartile ranges) and the rank-sum
test was used to analyze these values. Data of un-
ordered categories were denoted by rate, and differ-
ences in the rate between two groups were examined
through a chi-square test. Survival curves for ICU and
hospital duration were estimated using the Kaplan-
Meier method, and a log rank (Mantel-Cox) test was
used to estimate differences among these three anti-
fungal therapies. Correlation between variables was
tested by Spearman’s coefficient of rank correlation.
Variables found to be significantly associated with
mortality with a P-value < 0.01 at univariate analysis
were introduced into a logistic stepwise regression
model. All significant variables with collinearity were
excluded from the regression model. When deciding
which covariates to retain as candidate predictors for
the multivariable model, we considered the clinical
relevance of each covariate. The adjusted odds ratio of
dying and the 95% confidence interval for all inde-
pendent factors associated with mortality were calcu-
lated. Statistical analyses were performed with SPSS
16.0 (SPSS, Chicago, IL, USA), and a P value of < 0.05
was considered significant.
Fig. 1 China-SCAN study patients distribution and flowchart for this study
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Results
Baseline characteristics and risk factors of fungal infection
in ICI patients receiving antifungal therapy
Table 1 presents the baseline characteristics of the
patients whose data were analyzed in this study. As
shown in the table, there were no significant cross-group
differences in terms of gender, body weight, hospital
stays before ICU admission, ICU and hospital stays
before candidiasis onset, Acute Physiology and Chronic
Health Evaluation (APACHE) II score and sequential
organ failure assessment (SOFA) score on ICU admis-
sion, and accompanying underlying diseases. However,
the age of patents receiving initial targeted antifungal
therapy was higher than other two groups. Table 2 lists
the risk factors of fungal infection present within 2 weeks
(3 months for immunosuppressants) prior to study
entry, or at diagnosis, among 268 patients with ICI who
received antifungal therapy in the China-SCAN study.
The indwelling arterial catheterized in a significantly
lower proportion of patients in targeted therapy group
compared with other two groups (P < 0.05). The im-
munocompromised state, antibiotic therapy, clinical
procedures including life-sustaining treatments ≥ 24 h,
central venous catheterization, drainage and urethral
catheterization, gastrointestinal dysfunction, parenteral
nutrition, and surgery showed no significant differences
among the different therapy strategies.
Microbiological and clinical characteristics of ICI patients
receiving antifungal therapy
The candidiasis source of this study population was
mainly bloodstream infections, which accounted for
95.9% (257/268) of infections. Comparing the sources of
candidiasis among the three therapy strategies, only the
targeted group had more abdominal candidiasis infec-
tions (P = 0.026). C. albicans (107, 39.9%), C. parapsilosis
(42, 15.7%), C. tropicalis (37, 13.8%), and C. glabrata
(37, 13.8%) were the most prevalent species isolated,
with mixed infection were identified in 2/107 (1.9%), 1/42
(2.4%), 1/37 (2.7%), and 1/37 (2.7%) patients who received
antifungal therapy in this study. Further Candida species
were identified in < 2% of samples. 22 (8.2%) fungal iso-
lates with proven yeast forms that were most suggestive of
Candida spp. could not be further characterized. Based
on microbiological determination of MIC, the susceptibil-
ity to antifungal treatment was 89.9% (241/268) and the








Age, years 58.3 ± 21.6 58.3 ± 18.4 68.7 ± 16.2 0.001
Gender, n (%) 0.414
Male 98 (69.0) 40 (75.5) 47 (64.4)
Female 44 (31.0) 13 (24.5) 26 (35.6)
Body weight, kg 61.8 ± 10.7 63.5 ± 10.4 63.8 ± 10.1 0.473
Hospital stays before ICU admission, days 0.5 (10.0) 1.0 (4.5) 0.0 (11.5) 0.829
ICU stays before candidiasis onset, days 9.0 (17.0) 10.0 (14.5) 11.0 (33.0) 0.717
Hospital stays before candidiasis onset, days 16.5 (23.3) 12.0 (24.5) 16.0 (41.0) 0.461
Underlying disease, n (%)
Diabetic mellitus 28 (19.7) 13 (24.5) 21 (28.8) 0.318
Chronic cardiac dysfunctiona 23 (16.2) 14 (26.4) 17 (23.3) 0.210
Chronic obstructive pulmonary disease 15 (10.6) 6 (11.3) 12 (16.4) 0.449
Chronic renal insufficiencyb 12 (8.5) 5 (9.4) 13 (17.8) 0.108
Chronic hepatic insufficiencyc 4 (2.8) 1 (1.9) 6 (8.2) 0.111
Solid tumor 26 (18.3) 7 (13.2) 17 (23.3) 0.353
Haematological malignancy 2 (1.4) 1 (1.9) - 0.545
Illness severity at ICU admission
APACHE II score 20.0 ± 9.2 20.9 ± 8.1 21.5 ± 8.6 0.517
SOFA score 7.2 ± 3.7 7.7 ± 3.4 6.8 ± 3.8 0.434
Continuous variables are expressed as the means ± SD or medians (IQR). All the other data are raw numbers (%)
APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA sequential organ failure assessment
aAll patients corresponding to the New York Heart Association (NYHA) standards of level II or higher
bAll patients receiving long-term hemodialysis
cAs described according to APACHE II criteria: biopsy-proven cirrhosis and documented portal hypertension; episodes of past upper gastrointestinal bleeding
attributed to portal hypertension; or prior episodes of hepatic failure/encephalopathy/coma
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complete resistance rate was 6% (15/268). There were
no significant differences in the pathogenic Candida
species, susceptibility and duration of initial antifungal
medication between the three different treatment
groups. However, the initial antifungal agents differed
between the three groups, more caspofungin (37.7%)
were used in pre-emptive group while more voricona-
zole (28.8%) were used in targeted group. Compared
with empirical and targeted therapy group, the pre-
emptive group showed significantly higher microbio-
logical persistence (P = 0.011) and adjustment probability
after initial antifungal therapy (P < 0.05).
In addition of microbiological characteristics, the clin-
ical procedures and treatment outcomes of the 268 ICI
patients who received antifungal therapy were also listed
in the Table 3. There were no significant differences in
the APACHE II score, vasopressor administration, and
catheterization at ICI diagnosis between the three differ-
ent strategy groups. The SOFA score at ICI diagnosis
and immunopotentiation therapy including immuno-
globulin and thymosin were significantly higher while
the central venous catheter removed within 48 h after
first positive sample obtained were significantly lower in
pre-emptive group than in other two groups (P < 0.05).
Among the 268 ICI patients who received antifungal
therapy, the majority of patients (193/268, 72.0%) expe-
rienced clinical improvement, while complete clinical
remission occurred in only (94/268, 35.1%) patients. In
total, 59 patients withdrew from or decided to forego
comprehensive treatment, of whom 29 died in hospital
and 30 were discharged at their request. The overall ICU
or hospital mortality rates lists here were based on the
Table 2 Risk factors of fungal infection present within 2 weeks (3 months for immunosuppressants) prior to study entry, or at








Immune compromised, n (%)
Immunosuppressant therapya 5 (3.5) 3 (5.7) 5 (6.8) 0.535
HIV infection 1 (0.7) 1 (1.9) - 0.476
Neutropenia 3 (2.1) - - 0.260
Previous antibiotic therapy, n (%)b
cephalosporins 38 (26.8) 9 (17.0) 12 (16.4) 0.138
carbapenems 49 (34.5) 18 (34.0) 20 (27.4) 0.554
pennicillins 62 (43.7) 21 (39.6) 30 (41.1) 0.858
quinolones 17 (12.0) 8 (15.1) 9 (12.3) 0.839
glycopeptides 26 (18.3) 10 (18.9) 12 (16.4) 0.925
Life-sustaining treatments≥ 24 h
Invasive mechanical ventilation 113 (79.6) 47 (88.7) 60 (82.2) 0.337
vasopressor 47 (33.1) 12 (22.6) 19 (26.0) 0.286
Renal replacement therapy 8 (5.6) 5 (9.4) 8 (11.0) 0.345
Catheterization, n (%)c
central venous 113 (79.6) 45 (84.9) 66 (90.4) 0.122
indwelling arterial 27 (19.6) 13 (25.0) 6 (8.5) 0.040
drainage tube 52 (36.6) 26 (49.1) 23 (31.5) 0.124
urethral 104 (73.8) 43 (81.1) 53 (73.6) 0.534
Gastrointestinal dysfunction, n (%)d 72 (50.7) 32 (60.4) 45 (61.6) 0.229
Total parenteral nutrition, n (%) 70 (49.3) 30 (56.6) 41 (56.2) 0.513
Surgery, n (%) 59 (41.5) 24 (45.3) 25 (34.7) 0.457
Abdominal 33 (23.2) 20 (37.7) 18 (24.7) 0.114
Continuous variables are expressed as the means ± SD or medians (IQR). All the other data are raw numbers (%)
aVariables included steroid therapy, which defined as > 0.5 mg/(kg · day)−1 prednisone over 1 month (n = 7), cancer chemotherapy (n = 6), post-solid organ trans-
plant immunosuppression (n = 1), allogeneic bone marrow transplantation or allogeneic haematopoietic stem cell transplantation (n = 1), and tumor necrosis factor
therapy (n = 1) within 3 months prior to study entry
bAll patients receiving systemic drug therapy for ≥ 3 days within 2 weeks prior to study entry
cVariables included patients who required treatments were catheterized within 2 weeks of the first positive sample no matter the catheter was removed or not
before diagnosis
dVariables included hemorrhage, food intolerance, perforation, surgery, acalculouscholecystitis or intra-abdominal hypertension
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patients who died in the hospital or completed treat-
ment and were discharged at their physician’s discretion.
When all the 268 patients who received antifungal ther-
apy were included, the overall ICU mortality rate in
empirical, pre-emptive, and targeted therapy groups
decreased to 42 (29.6%), 26 (49.1%), and 27 (37.0%), re-
spectively (P = 0.039); and the overall hospital mortality
rate in these three groups decreased to 43 (30.3%), 27
(50.9%), and 29 (39.7%), respectively (P = 0.025). Although
Table 3 Microbiological and clinical characteristics among 268 ICI








Source of candidiasis, n (%)a
Blood culture 138 (97.2) 51 (96.2) 68 (93.2) 0.366
Proven catheter-relatedb 12 (8.5) 10 (18.9) 7 (6.8) 0.056
Abdominal 2 (1.4) 1 (1.9) 6 (8.2) 0.026
Intracranial 1 (0.7) 1 (1.9) 1 (1.4) 0.762
Pulmonary - 1 (1.9) - 0.131
Pleural 1 (0.7) - - 0.641
Pathogenic Candida species, n (%)c
C. albicans 56 (39.4) 20 (37.7) 31 (42.5) 0.854
C.tropicalis 18 (12.7) 10 (18.9) 9 (12.3) 0.490
C.glabrata 18 (12.7) 11 (20.8) 8 (11.0) 0.247
C.parapsilosis 21 (14.8) 7 (13.2) 14 (19.2) 0.605
Uncategorized 11 (7.7) 5 (9.4) 6 (8.2) 0.930
Initial antifungal therapyd
Categories, n (%)e
fluconazole 61 (43.0) 16 (30.2) 24 (32.9) 0.160
caspofungin 27 (19.0) 20 (37.7) 17 (23.3) 0.024
voriconazole 20 (14.1) 8 (15.1) 21 (28.8) 0.025
Susceptibility, n (%)
susceptible 125 (88.0) 48 (90.6) 68 (93.2) 0.490
completely resistant 9 (6.3) 3 (5.7) 3 (4.1) 0.797
Duration, days 8.5 (10.0) 6.0 (9.8) 7.0 (12.0) 0.932
Drug Adjustment,
n (%)
67 (47.2) 35 (66.0) 30 (41.1) 0.017
Procedures at diagnosis, n (%)
APACHE II score 19.5 ± 8.1 20.9 ± 8.8 21.2 ± 7.4 0.517
SOFA score 6.7 ± 3.5 8.2 ± 4.1 6.2 ± 3.7 0.010
Vasopressor 44 (31.0) 18 (34.0) 21 (28.8) 0.824
Catheterization, n (%)f
central venous 90 (64.7) 37 (69.8) 58 (79.5) 0.086
indwelling arterial 19 (13.8) 9 (17.3) 5 (7.0) 0.202
drainage tube 37 (26.8) 21 (42.0) 21 (29.6) 0.133
urethral 100 (70.9) 41 (77.4) 52 (72.2) 0.668
Central venous catheter
removed within 48 h
after first positive
sample obtained, n (%)
102 (71.8) 28 (52.8) 49 (67.1) 0.043
Drainage catheter
removed within 48 h
after first positive
sample obtained, n (%)
16 (11.3) 6 (11.3) 8 (11.0) 0.997
Immunopotentiation
therapy, n (%)g
55 (38.7) 32 (60.4) 34 (46.6) 0.025
Microbiological evaluation, n (%)
Eradication 73 (51.4) 27 (50.9) 36 (49.3) 0.958
Table 3 Microbiological and clinical characteristics among 268 ICI
patients receiving antifungal therapy in the China-SCAN study
(Continued)
Persistence 6 (4.2) 9 (17.0) 9 (12.3) 0.011
Clinical resolution, n (%) 0.045
Complete remission 61 (43.3) 11 (21.2) 22 (30.1) 0.009
Improvement 105 (74.5) 35 (67.3) 53 (72.6) 0.613
Clinical outcome
ICU mortality, n (%)h 42 (32.1) 26 (57.8) 27 (43.5) 0.008
Hospital mortality,
n (%)h
43 (32.8) 27 (60.0) 29 (46.8) 0.004
ICU duration, days 26.0 (30.5) 26.0 (26.0) 33.0 (44.8) 0.473
Hospital duration, days 44.0 (50.0) 32.0 (47.0) 44.0 (62.8) 0.357
Continuous variables are expressed as the means ± SD or medians (IQR). All
the other data are raw numbers (%)
APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA sequential
organ failure assessment
aDiagnostic confirmation was based solely on at least one positive blood
culture in 257 (95.9%) cases, on positive fluid culture from a normally sterile
site (cerebral spinal fluid, ascitic fluid or pleural fluid) in 10 (3.7%) cases and on
candidaemia combined with positive culture from a normally sterile site in 3
(1.1%) cases. Diagnosis was confirmed by histopathology in 1 patient (0.3%)
bThe catheter-related blood stream infection was diagnosed according to a
previous study (Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP, Raad
II, Rijnders BJ, Sherertz RJ, Warren DK: Clinical practice guidelines for the diagnosis
and management of intravascular catheter-related infection: 2009 Update by the
Infectious Diseases Society of America. Clin Infect Dis 2009, 49: 1–45)
cC. albicans,C. tropicalis,C. glabrata, and C. parapsilosis were the most prevalent
species isolated. But some sample was not pure infected by single fungi from
these four fungal. That is to say, mixed fungal infection existed. The
proportion of C. albicans,C. tropicalis,C. glabrata, and C. parapsilosis combined
others fungi were 1.9% (2/107), 2.7% (1/37), 2.7% (1/37), 2.4% (1/42),
respectively. Uncategorized Candida species included the fungal isolates with
proven yeast forms that were most suggestive of Candida spp. without further
characterization (n = 22)
dFirst-line treatment comprised drug combination in 4/268 (1.5%) patients, 1
(0.9%) in empirical therapy group, 1 (1.2%) in pre-emptive therapy group, and
2 (2.6%) in targeted therapy group
eFluconazole (101/268; 37.7%), caspofungin (64/268; 23.9%), and voriconazole
(49/268; 18.3%) were the most widely used first-line agents
fAll patients who were catheterized when the first positive samples
were collected
gVariable included immunoglobulin and thymosin
hAmong 268 ICI patients receiving anti-fungal therapy in China-SCAN study, 59
patients withdrew from or decided to forego comprehensive treatment, of
whom 29 died in hospital and 30 were discharged at their requests. The ICU
or hospital mortality rate listed here was based only on patients who died in
hospital or completed treatment and were discharged at their physician’s
discretion. The overall ICU mortality rate in empirical therapy, pre-emptive
therapy, and targeted therapy groups decreased to 42 (29.6%), 26 (49.1%),
and 27 (37.0%), respectively (P = 0.039); and the overall hospital mortality rate
in these three groups decreased to 43 (30.3%), 27 (50.9%), and 29 (39.7%),
respectively (P = 0.025) when all the 268 patients who received antifungal
therapy were included
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duration of hospital stay and ICU stay after infection did
not significantly differ among the three groups, the em-
pirical therapy group had the highest clinical complete
remission, lowest ICU mortality and hospital mortality
compared to the other two groups (P < 0.01). From Kaplan-
Meier analysis, the empirical therapy group had the
highest survival probabilities after fungal infection for
hospital duration (P = 0.021) rather than ICU duration
(P = 0.117) (Fig. 2).
Clinical differences between survivors and non-survivors
receiving antifungal therapy
Analysis of the risk factors for mortality revealed a
higher risk with increasing age and higher APACHE II
score and SOFA score on ICU admission (P < 0.05).
Among patients in the non-survivor group, the APA-
CHE II score and SOFA score at the time of ICI diag-
nostic confirmation were significantly higher than those
in the survivor group (P < 0.01). Additionally, vasopres-
sor administration and central venous catheterization at
ICI diagnosis occurred in a significantly higher propor-
tion of patients in the non-survivor group compared
with patients in the survivor group (P < 0.05). More im-
portantly, the choice of initial antifungal therapy strategy
differed significantly between the two groups (P = 0.004),
more patients received empirical antifungal therapy in
survivors than in non-survivors (P < 0.05) (Table 4).
Risk factors for hospital mortality in ICI patients receiving
different antifungal therapy strategies
Variables found to be significantly associated with mor-
tality with a P value < 0.01 at univariate analysis were
introduced into a logistic stepwise regression model
(Table 5). All significant variables with collinearity were
excluded from the regression model. The first multivari-
ate analysis was performed by introducing APACHE II
and SOFA score on ICU admission as independent
factors (Table 6) and the second one was performed by
introducing APACHE II and SOFA score at ICI diagno-
sis as independent factors (Table 7). This was motivated
by the fact that both the collinearity between APACHE
II on ICU admission and at ICI diagnosis (r2 = 0.51,
P < 0.001) and SOFA score on ICU admission and at
ICI diagnosis (r2 = 0.48, P < 0.001) were high.
The results showed that the APACHE II score on ICU
admission (odds ratio 1.047, P = 0.004), which suggested
risk factor for poor prognosis. Compared with pre-
emptive therapy strategy, the empirical therapy may be a
protective factor for poor prognosis on ICU admission
and at ICI diagnosis (odds ratio 0.327, 95% confidence
interval 0.160–0.667, P = 0.002; odds ratio 0.351, 95%
confidence interval 0.168–0.735, P = 0.006).
Discussion
IFI is one of the common infections in the ICU with a
high level of mortality rate. A large number studies of
anti-bacterial infection treatment suggested that prompt
early empirical strategies of antibiotic usage is an im-
portant factor affecting anti-infection treatment effects
and prognosis [16, 17]. However, whether this therapy
strategy can be used in antifungal therapy remains
unclear. In addition, previous studies relevant to the
strategy of antifungal infections were carried out in
fungal high-risk populations, including patients with
non-fungal infections and confirmed fungal infections.
Identification of patients at risk of Candida infections
will inevitably impact the results for the appropriate
antifungal treatment time. We selected 306 patients
diagnosed with ICI from the China-SCAN study, which
is the only study to assess antifungal therapy among
patients in ICU diagnosed with ICIs. It excluded the high-
risk patients with non-fungal infections, which maybe more
Fig. 2 Kaplan-Meier analyses of survival probabilities after fungal infection among 268 ICI patients receiving antifungal therapy in the China-SCAN
study. Survival was measured according to empirical, pre-emptive, and targeted therapy strategies. Survival time was censored on ICU discharge
(a) or hospital discharge (b). Cum Surv: cumulative survivors
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Table 4 Risk factors for hospital mortality in 268 ICI patients receiving antifungal therapy in the China-SCAN study based only on






Age, years 58.6 ± 20.6 66.0 ± 19.8 0.006
Gender, n (%) 0.259
Male 91 (65.5) 72 (72.7)
Female 48 (34.5) 27 (27.3)
Body weight, kg 62.2 ± 10.4 62.4 ± 11.0 0.891
APACHE II score on ICU admission 19.0 ± 8.9 22.5 ± 8.4 0.002
SOFA score on ICU admission 6.6 ± 3.5 7.9 ± 3.8 0.008
Underlying disease, n (%)
Diabetic mellitus 25 (18.0) 28 (28.3) 0.081
Chronic cardiac dysfunctiona 26 (18.7) 26 (26.3) 0.203
Chronic obstructive pulmonary disease 16 (11.5) 15 (15.2) 0.439
Chronic renal insufficiencyb 11 (7.9) 16 (16.2) 0.062
Chronic hepatic insufficiencyc 4 (2.9) 7 (7.1) 0.208
Solid tumor 22 (15.8) 25 (25.3) 0.098
Haematological malignancy 1 (0.7) 2 (2.0) 0.572
Immune compromised, n (%)
Immunosuppressant therapyd 4 (2.9) 6 (6.1) 0.327
HIV infection - 1 (1.0) 0.416
Neutropenia 1 (0.7) 2 (2.0) 0.572
Source of candidiasis, n (%)e
Blood culture 135 (97.1) 96 (97.0) 0.999
Other sterile site 5 (3.6) 5 (5.1) 0.745
Pathogenic Candida species, n (%)f 0.321
C. albicans 55 (39.6) 38 (38.4) 0.893
C.tropicalis 21 (15.1) 11 (11.1) 0.443
C.glabrata 15 (10.8) 18 (18.2) 0.128
C.parapsilosis 20 (14.4) 18 (18.2) 0.475
Initial antifungal therapy
Strategies, n (%) 0.004
empirical therapy 66 (47.5) 35 (35.4) 0.041
pre-emptive therapy 37 (26.6) 35 (35.4) 0.155
Targeted therapy 36 (25.9) 29 (29.3) 0.658
Categories, n (%)g 0.348
fluconazole 54 (38.8) 34 (34.3) 0.499
caspofungin 34 (24.5) 21 (21.2) 0.640
voriconazole 22 (15.8) 25 (25.3) 0.098
Susceptibility, n (%)
susceptible 122 (87.8) 89 (89.9) 0.682
completely resistant 9 (6.5) 6 (6.1) 0.999
Duration, days 8.0 (10.0) 6.0 (11.0) 0.428
Drug Adjustment, n (%) 62 (44.6) 54 (54.5) 0.149
Procedures within 2 weeks prior to diagnosis, n (%)
Life-sustaining treatments≥ 24 h
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objective and valuable. Additionally, we are not targeted
to specific populations for analysis, such as bone mar-
row transplantation, leukemia, or liver transplantation.
Therefore, prophylaxis was not discussed here. This
study revealed that the initial empirical antifungal ther-
apy can reduce hospital mortality and have longer
hospital duration for patients with severe ICIs com-
pared with the pre-emptive therapy. The appropriate
initial antifungal therapeutic strategy chosen was an
independent predicting factor for the prognosis of se-
vere ICIs. It seemed that initial empirical antifungal
therapy could be critical to decrease hospital mortality.
It has been recognized that early presumptive anti-
fungal therapy is associated with improved clinical out-
comes and reduced mortality of ICIs [18–20]. We also
found similar results that empirical antifungal therapy
Table 4 Risk factors for hospital mortality in 268 ICI patients receiving antifungal therapy in the China-SCAN study based only on
patients who died in hospital or completed treatment and were discharged at their physician’s discretion (Continued)
Invasive mechanical ventilation 109 (78.4) 87 (87.9) 0.084
vasopressor 38 (27.3) 33 (33.3) 0.389
Renal replacement therapy 7 (5.0) 12 (12.1) 0.055
Catheterization, n (%)h
central venous 113 (81.3) 87 (87.9) 0.210
indwelling arterial 24 (17.8) 21 (21.9) 0.501
drainage tube 53 (38.1) 38 (38.4) 0.999
urethral 101 (73.2) 81 (81.8) 0.160
Gastrointestinal dysfunction, n (%)i 79 (56.8) 54 (54.5) 0.791
Total parenteral nutrition, n (%) 70 (50.4) 54 (54.5) 0.599
Surgery, n (%) 60 (43.2) 35 (35.7) 0.283
Abdominal 39 (28.1) 25 (25.3) 0.659
Procedures at diagnosis, n (%)
APACHE II score 18.8 ± 8.5 22.7 ± 7.0 0.000
SOFA score 6.4 ± 3.6 7.8 ± 3.8 0.003
Vasopressor 37 (26.6) 39 (39.4) 0.048
Catheterization, n (%)j
central venous 88 (64.2) 76 (77.6) 0.031
indwelling arterial 20 (14.8) 13 (13.5) 0.850
drainage tube 40 (29.6) 32 (34.0) 0.563
urethral 97 (70.3) 79 (79.8) 0.132
Central venous catheter removed within 48 h after first positive sample obtained, n (%) 92 (66.2) 70 (70.7) 0.484
Drainage catheter removed within 48 h after first positive sample obtained, n (%) 19 (13.7) 8 (8.1) 0.216
Immunopotentiation therapy, n (%)k 55 (39.6) 51 (51.5) 0.085
Continuous variables are expressed as the means ± SD or medians (IQR). All the other data are raw numbers (%)
APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA sequential organ failure assessment
aAll patients corresponding to the NYHA standards of level II or higher
bAll patients receiving long-term hemodialysis
cAs described according to the APACHE II criteria: biopsy-proven cirrhosis and documented portal hypertension; episodes of past upper gastrointestinal bleeding
attributed to portal hypertension; or prior episodes of hepatic failure/encephalopathy/coma
dVariables included steroid therapy, which defined as >0.5 mg/(kg · day)−1 prednisone over 1 month (n = 7), cancer chemotherapy (n = 6), post-solid organ transplant
immunosuppression (n = 1), allogeneic bone marrow transplantation or allogeneic haematopoietic stem cell transplantation (n = 1), and tumor necrosis factor therapy
(n = 1) within 3 months prior to study entry
eDiagnostic confirmation of other sterile sites was based on positive fluid culture from a normally sterile site (cerebral spinal fluid, ascitic fluid or pleural fluid) in
10 (3.7%) cases and on histopathology in one patient (0.3%); Diagnosis was confirmed by candidaemia combined with positive culture from a normally sterile site
in 3 (1.1%) cases
fC. tropicalis, C. glabrata, and C. parapsilosis were the most prevalent non-C. albicans species isolated, which were identified in >98% of samples
gFirst-line treatment comprised a single agent in 264/268 (98.5%) patients, most commonly fluconazole (101/268;37.7%), caspofungin (64/268; 23.9%), and
voriconazole (49/268; 18.3%)
hVariables included patients who required treatments were catheterized within 2 weeks of the first positive sample no matter the catheter was removed or not
before diagnosis
iVariable included haemorrhage, food intolerance, perforation, surgery, acalculouscholecystitis or intra-abdominal hypertension
jAll patients who were catheterized when the first positive samples were collected
kVariable included immunoglobulin and thymosin
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helps to improve clinical complete remission, reduce the
incidence of persistent fungal infection rate, and lower
the hospital mortality in patients with severe ICIs com-
pared with pre-emptive therapy. As is well known, signs
and symptoms of candidiasis are nonspecific, and micro-
biological and imaging techniques lack sensitivity and
specificity. Thus, early diagnosis of invasive candidiasis
remains a challenge. Several placebo-controlled studies
revealed that pre-emptive therapy could not reduce the
incidence of ICIs or survival free of invasive fungal infec-
tion [21, 22]. Knitsch, et al showed that pre-emptive
therapy was non-effective in preventing ICIs in high-risk
surgical ICU patients with intra-abdominal infections
due to the drug being administered too late [23]. In
contrast with empirical therapy, pre-emptive therapy
must have indirect evidence for fungal infections that
the widespread use of antifungal therapies must be
balanced against the risk of toxicity, costs, and the
emergence of resistance. In this study, the patients in-
cluded had confirmed ICIs rather than suspected fun-
gal infections or non-fungal infections. Therefore, the
“diagnostic” advantage of pre-emptive therapy and tar-
geted therapy did not exist. This may be an important
reason for early empirical antifungal therapy that could
significantly improve clinical outcomes in patients with
severe ICIs.
It has been shown that the lack of experience in treat-
ment leading to improper drug selection could be an
important risk factor for poor prognosis [24]. The results
of this study showed that during the initial antifungal
treatment, the empirical therapy group selected more
fluconazole; the pre-emptive therapy group selected
more caspofungin; and the targeted therapy group se-
lected more voriconazole, which were partly consistent
with the recommended guidelines [12, 13]. In addition,
there was no statistical significance in antifungal drug
sensitivity and the duration of drug administration
among these three strategies. This result suggested that
depending on the combination of local epidemiological
survey data and guidelines, pre-emptive and targeted
antifungal therapy had no advantage than empirical
therapeutic strategy in clinical efficacy and safety. Inter-
estingly, we also found that the drug adjustments for
pre-emptive therapy after the initial antifungal therapy
was significantly higher compared with the empirical
therapy and targeted therapy groups (P = 0.017) in this
study. It further confirmed the credibility and feasibility
of empirical antifungal therapy, which could be another
important reason for empirical therapy that significantly
improves the clinical prognosis of ICI patients. Con-
versely, delaying the start time of the antifungal infection
treatment is undoubtedly detrimental.
It has been demonstrated that critically ill ICU pa-
tients have complicated conditions. In the initial treat-
ment strategy of the antifungal treatment evaluation
process, including the basic conditions of the patient
(severity of illness, invasive operation, gastrointestinal
function, recent surgical history, previously selected
types of antibiotics and antifungal drugs and other fac-
tors) is important as these conditions are likely to have
an impact on prognosis and assessment. To further
enhance the objectivity and accuracy of the assessment,
all these risk factors are compared using statistical ana-
lysis. Diagnostic confirmation was based solely on at least
one positive blood culture in 257 (95.9%) cases. Only 27
(10.8%) cases finally proved incidence of a catheter-related
blood stream infection, and the reason for the lower
incidence has been reported by Hu, et al on behalf of
China-SCAN [25]. There was no significant difference
among the three different strategies for abdominal sources
Table 5 Variables included in univariate logistic regression and
significant associated (P < 0.01) with hospital mortality in 268 ICI
patients receiving antifungal therapy in the China-SCAN study
based only on patients who died in hospital or completed






Age, years 58.6 ± 20.6 66.0 ± 19.8 0.006
APACHE II score on ICU admission 19.0 ± 8.9 22.5 ± 8.4 0.002
SOFA score on ICU admission 6.6 ± 3.5 7.9 ± 3.8 0.008
APACHE II score at diagnosis 18.8 ± 8.5 22.7 ± 7.0 0.000
SOFA score at diagnosis 6.4 ± 3.6 7.8 ± 3.8 0.003
Initial antifungal therapy strategies
(empirical : pre-emptive : targeted)
66 : 37 : 36 35 : 35 : 29 0.004
APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA sequential
organ failure assessment
Continuous variables are expressed as the means ± SD or medians (IQR). All
the other data are raw numbers (%)
Table 6 Multivariate analysis for hospital mortality in 268 ICI patients receiving antifungal therapy in the China-SCAN study with
APACHE II and SOFA score on ICU admission as independent factors
Variables B SE Wald’s coefficient OR 95% CI for OR P-value
Lower Upper
APACHE II score on ICU admission 0.046 0.016 8.389 1.047 1.015 1.080 0.004
Initial antifungal therapy strategies
(empirical : pre-emptive : targeted)
10.127 0.006
Empirical : Pre-emptive −1.117 0.363 9.449 0.327 0.160 0.667 0.002
APACHE II Acute Physiology and Chronic Health Evaluation II
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of candidiasis. Maybe the absence of adequate abdominal
source control caused late abdominal fungal infections,
which led to a more targeted antifungal therapy after
direct etiological evidence was found rather than early
administration. Regarding the pathogenic Candida spe-
cies, there was no significant difference [26]. Similar to
other studies [27], the proportion of non-albicans Can-
dida infection (60.1%) was higher than that of Candida
albicans (39.9%) in this study population. Fortunately, the
vast majority of Candida detected was susceptible to
antifungal drugs. Because all patients in this study were
diagnosed with ICI during hospitalization in ICU and the
limitation of ICI occurrence influenced survival time after
infection, it was more useful to compare the length of
ICU and total hospitalization time to reflect the actual
effectiveness of antifungal infection treatment. Therefore,
Kaplan-Meier survival analysis revealed that ICI patients
with initial pre-emptive antifungal therapy and initial
targeted antifungal therapy were associated with a reduced
hospital duration compared with patients with initial
empirical antifungal therapy after confirmation of fungal
infection (log-rank test: P = 0.021). This indicator was
strongly demonstrated that early appropriate empirical
antifungal therapy, which helps prolong the hospital
survival time of patients with severe ICIs, may lay a solid
foundation for reduced hospital mortality.
Our study has several limitations. First, this study only
included patients diagnosed with ICI, which may provide
a more clear influence of different strategies on ICIs.
However, we did not evaluate the role of different strat-
egies for the patients with a suspected ICI but no ICI
confirmation. Second, although the China-SCAN study
was a multi-center, observational study, the results of this
study were based on statistical analysis rather than a pro-
spective study on treatment strategies. Therefore, another
RCT is needed to further confirm the direct effect of
different therapeutic strategies on bacteriological and clin-
ical prognosis. Third, 59 patients withdrew from or de-
cided to forego comprehensive treatment in this study, 29
of whom died in the hospital and 30 were discharged at
their request. The ICU or hospital mortality rate listed
here was based only on patients who died in the hospital
or completed treatment and were discharged at their phy-
sician’s discretion. We do not exclude the fact that this
might have impacted the results of our statistical analysis.
Conclusions
In summary, the initial antifungal treatment strategy
formulation is an independent risk factor for the prog-
nosis of patients with an ICI. Selecting the appropriate
timing of the initial antifungal treatment could help
improve the clinical cure rate, reduce the incidence of
persistent fungal infection, and lower hospital mortality
in patients with severe ICIs. This finding is consistent
with the treatment strategy of resistance to bacterial
infections. However, this conclusion has yet to be
confirmed by a prospective RCT study in the future.
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